株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

止血剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2018~2022年)

Hemostatic Agents Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2022

発行 Transparency Market Research 商品コード 763043
出版日 ページ情報 英文 435 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
止血剤市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2018~2022年) Hemostatic Agents Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2022
出版日: 2018年11月09日 ページ情報: 英文 435 Pages
概要

当レポートでは、世界の止血剤市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査の意図と調査範囲

第2章 仮定と調査方法

第3章 市場概要

第4章 プレミアムインサイト

  • 全体的価格評価
    • 止血剤価格動向
  • 国別価格評価
  • 法規制償還評価
  • 主要製品の比較評価
  • 主な流通業者

第5章 北米市場

  • 米国
  • カナダ

第6章 欧州市場

  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第7章 アジア太平洋地域

  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第8章 南アフリカ市場

第9章 その他の諸国市場

  • 製品タイプ別
  • 専門/治療分野別
  • 病院規模別

第10章 企業プロファイル

  • Baxter
  • Ethicon US, LLC.
  • C. R. Bard, Inc.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Z-Medica, LLC.
  • CryoLife, Inc.
  • Integra LifeSciences
  • Advanced Medical Solutions Group plc
  • GELITA AG
図表

List of Tables

  • Table 01: Hemostatic Agents Market Value (US$ Mn), by Regions, 2015-2022
  • Table 02: Pricing Analysis - U.S.
  • Table 03: Pricing Analysis - Canada
  • Table 04: Pricing Analysis - Germany
  • Table 05: Pricing Analysis - France
  • Table 06: Pricing Analysis - U.K.
  • Table 07: Pricing Analysis - Spain
  • Table 08: Pricing Analysis - Italy
  • Table 09: Pricing Analysis - China
  • Table 10: Pricing Analysis - India
  • Table 11: Pricing Analysis - Australia
  • Table 12: Pricing Analysis - Japan
  • Table 13: Pricing Analysis - South Korea
  • Table 14: Pricing Analysis - South Africa
  • Table 15: Comparative Assessment of Key Products
  • Table 16: U.S. Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 17: U.S. Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 18: Brand Assessment: Most Popular Hemostatic Brands - U.S.
  • Table 19: Criss-cross Assessment - Product vs. Specialty - U.S.
  • Table 20: Selection Criteria for Products, by Specialty / Therapeutic Area - U.S.
  • Table 21: U.S. Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 22: Concentration of Hospitals in U.S., by State
  • Table 23: Detailed Hospital Segmentation in U.S., by Bed Size
  • Table 24: Canada Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 25: Canada Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 26: Brand Assessment: Most Popular Hemostatic Brands - Canada
  • Table 27: Criss-cross Assessment - Product vs. Specialty - Canada
  • Table 28: Selection Criteria for Products, by Specialty / Therapeutic Area - Canada
  • Table 29: Canada Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 30: Concentration of Hospitals in Canada, by State
  • Table 31: Detailed Hospital Segmentation in Canada, by Bed Size
  • Table 32: Germany Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 33: Germany Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 34: Brand Assessment: Most Popular Hemostatic Brands - Germany
  • Table 35: Criss-cross Assessment - Product vs. Specialty - Germany
  • Table 36: Selection Criteria for Products, by Specialty / Therapeutic Area - Germany
  • Table 37: Germany Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 38: Concentration of Hospitals in Germany, by State
  • Table 39: Detailed Hospital Segmentation in Germany, by Bed Size
  • Table 40: France Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 41: France Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 42: Brand Assessment: Most Popular Hemostatic Brands - France
  • Table 43: Criss-cross Assessment - Product vs. Specialty - France
  • Table 44: Selection Criteria for Products, by Specialty / Therapeutic Area - France
  • Table 45: France Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 46: Concentration of Hospitals in France, by State
  • Table 47: Detailed Hospital Segmentation in France, by Bed Size
  • Table 48: U.K. Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 49: U.K. Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 50: Brand Assessment: Most Popular Hemostatic Brands - U.K.
  • Table 51: Criss-cross Assessment - Product vs. Specialty - U.K.
  • Table 52: Selection Criteria for Products, by Specialty / Therapeutic Area - U.K.
  • Table 53: U.K. Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 54: Concentration of Hospitals in U.K., by State
  • Table 55: Detailed Hospital Segmentation in U.K., by Bed Size
  • Table 56: Spain Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 57: Spain Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 58: Brand Assessment: Most Popular Hemostatic Brands - Spain
  • Table 59: Criss-cross Assessment - Product vs. Specialty - Spain
  • Table 60: Selection Criteria for Products, by Specialty / Therapeutic Area - Spain
  • Table 61: Spain Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 62: Concentration of Hospitals in Spain, by State
  • Table 63: Detailed Hospital Segmentation in Spain, by Bed Size
  • Table 64: Italy Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 65: Italy Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 66: Brand Assessment: Most Popular Hemostatic Brands - Italy
  • Table 67: Criss-cross Assessment - Product vs. Specialty - Italy
  • Table 68: Selection Criteria for Products, by Specialty / Therapeutic Area - Italy
  • Table 69: Italy Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 70: Concentration of Hospitals in Italy, by State
  • Table 71: Detailed Hospital Segmentation in Italy, by Bed Size
  • Table 72: China Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 73: China Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 74: Brand Assessment: Most Popular Hemostatic Brands - China
  • Table 75: Criss-cross Assessment - Product vs. Specialty - China
  • Table 76: Selection Criteria for Products, by Specialty / Therapeutic Area - China
  • Table 77: China Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 78: Concentration of Hospitals in China, by State
  • Table 79: Detailed Hospital Segmentation in China, by Bed Size
  • Table 80: India Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 81: India Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 82: Brand Assessment: Most Popular Hemostatic Brands - India
  • Table 83: Criss-cross Assessment - Product vs. Specialty - India
  • Table 84: Selection Criteria for Products, by Specialty / Therapeutic Area - India
  • Table 85: India Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 86: Concentration of Hospitals in India, by State
  • Table 87: Detailed Hospital Segmentation in India, by Bed Size
  • Table 88: Australia Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 89: Australia Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 90: Brand Assessment: Most Popular Hemostatic Brands - Australia
  • Table 91: Criss-cross Assessment - Product vs. Specialty - Australia
  • Table 92: Selection Criteria for Products, by Specialty / Therapeutic Area - Australia
  • Table 93: Australia Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 94: Concentration of Hospitals in Australia, by State
  • Table 95: Detailed Hospital Segmentation in Australia, by Bed Size
  • Table 96: Japan Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 97: Japan Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 98: Brand Assessment: Most Popular Hemostatic Brands - Japan
  • Table 99: Criss-cross Assessment - Product vs. Specialty - Japan
  • Table 100: Selection Criteria for Products, by Specialty / Therapeutic Area - Japan
  • Table 101: Japan Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 102: Concentration of Hospitals in Japan, by State
  • Table 103: Detailed Hospital Segmentation in Japan, by Bed Size
  • Table 104: South Korea Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 105: South Korea Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 106: Brand Assessment: Most Popular Hemostatic Brands - South Korea
  • Table 107: Criss-cross Assessment - Product vs. Specialty - South Korea
  • Table 108: Selection Criteria for Products, by Specialty / Therapeutic Area - South Korea
  • Table 109: South Korea Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 110: Concentration of Hospitals in South Korea, by State
  • Table 111: Detailed Hospital Segmentation in South Korea, by Bed Size
  • Table 112: South Africa Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 113: South Africa Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 114: Brand Assessment: Most Popular Hemostatic Brands - South Africa
  • Table 115: Criss-cross Assessment - Product vs. Specialty - South Africa
  • Table 116: Selection Criteria for Products, by Specialty / Therapeutic Area - South Africa
  • Table 117: South Africa Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022
  • Table 118: Concentration of Hospitals in South Africa, by State
  • Table 119: Detailed Hospital Segmentation in South Africa, by Bed Size
  • Table 120: Rest of the World (RoW) Hemostatic Agents Market Value (US$ Mn), by Product, 2015-2022
  • Table 121: Rest of the World (RoW) Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015-2022
  • Table 122: Rest of the World (RoW) Hemostatic Agents Market Forecast, by Size of Hospital, 2015-2022

List of Figures

  • Figure 01: Hemostatic Agents Market Value (US$ Mn), 2015-2022
  • Figure 02: Global Hemostatic Agents Market Share Analysis (2017)
  • Figure 03: Selection Criteria for Distributors- U.S.
  • Figure 04: Selection Criteria for Distributors - Canada
  • Figure 05: Selection Criteria for Distributors - Germany
  • Figure 06: Selection Criteria for Distributors - France
  • Figure 07: Selection Criteria for Distributors - U.K.
  • Figure 08: Selection Criteria for Distributors - Spain
  • Figure 09: Selection Criteria for Distributors - Italy
  • Figure 10: Selection Criteria for Distributors - China
  • Figure 11: Selection Criteria for Distributors - India
  • Figure 12: Selection Criteria for Distributors - Australia
  • Figure 13: Selection Criteria for Distributors - Japan
  • Figure 14: Selection Criteria for Distributors - South Korea
  • Figure 15: Selection Criteria for Distributors - South Africa
  • Figure 16: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 17: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 18: Johnson & Johnson Breakup of Net Sales, by Region, 2017
  • Figure 19: Johnson & Johnson Breakup of Net Sales (%), by Business Segment, 2017
  • Figure 20: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 21: Baxter R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 22: Baxter Breakup of Net Sales, by Region, 2017
  • Figure 23: Baxter Breakup of Net Sales (%), by Business Segment, 2017
  • Figure 24: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 25: Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015-2017
  • Figure 26: Pfizer, Inc. Breakup of Net Sales, by Business Segment, 2017
  • Figure 27: Pfizer, Inc. Breakup of Net Sales (%), by Region, 2017
  • Figure 28: CryoLife, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 29: CryoLife, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 30: CryoLife, Inc. Breakup of Net Sales, by Region, 2017
  • Figure 31: CryoLife, Inc. Breakup of Net Sales (%), by Business Segment, 2017
  • Figure 32: C. R. Bard, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2016
  • Figure 33: C. R. Bard, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2016
  • Figure 34: C. R. Bard, Inc. Breakdown of Net Sales, by Region, 2016
  • Figure 35: C. R. Bard, Inc. Breakdown of Net Sales (%), by Business Segment, 2016
  • Figure 36: CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 37: CSL Behring R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 38: CSL Behring Net Profit, Y-o-Y, 2014-2017
  • Figure 39: CSL Behring Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 40: B. Braun Melsungen AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 41: B. Braun Melsungen AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 42: B. Braun Melsungen AG Breakdown of Net Sales (%), by Region, 2017
  • Figure 43: B. Braun Melsungen AG Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 44: Takeda Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 45: Takeda Pharmaceutical R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 46: Takeda Pharmaceutical Sales, by Region, 2017
目次

Title:
Hemostatic Agents Market (Product Type - Active Agents, Passive Agents, Combination; Specialty and Therapeutic Area - Cardiology, Cath Lab, Trauma, General Surgery, ObGyn, Transplant, Oncology, Neurology, Orthopedic, Plastic Surgery, Dental, Others (Urological Surgeries, Pulmonary Surgeries); Size of Hospitals - 500+ Beds, 250-499 Beds, Less than 250 Beds) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2022.

Hemostatic Agents Market - Overview

Hemostasis is the physiological process to stop the bleeding, or blood flow via a blood vessel, or hemorrhage. A clot is formed at injury site in hemostasis and results in repairing of blood vessels. The main components of hemostasis are primary hemostasis, secondary hemostasis, and fibrinolysis. At the time of a blood vessel injury, platelets gather together to form a plug. In hemostasis, an interaction of proteins, known as clotting factors, forms a fibrin mesh to hold the platelets intact, thereby resulting in the injury healing while not letting the blood escape from the blood vessel. Hemostatic agents are utilized to stem blood flow and enhance clotting and hemostasis by speeding up the coagulation process. These agents enhance hemostasis by progressing primary hemostasis, boosting the formation of fibrin, or inhibiting fibrinolysis. Hemostatic agents play a prominent and vital role in the treatment or prevention of excessive or disruptive blood flow, thereby indicating their importance and use in treatments in various therapeutic areas. According to JEMS (Journal of Emergency Medical Services), traumatic and non-traumatic causes of hemorrhage carry remarkable morbidity and mortality.

Rise in the geriatric population, increase in number of surgical procedures, research & developments, and advancements in the fields of healthcare and life sciences, rise in public health awareness and measures have led to the introduction of appropriate and effective treatments for diseases. Consistent rise in geriatric population requiring treatments in various therapeutic areas fuels the demand for hemostatic agents in order to prevent the disruptive blood loss. This provides significant opportunity for key players operating in the market. Key players are introducing different strategies of launching products and acquisitions, along with appropriate marketing and strong distributors and hospitals network, thereby boosting the hemostatic agents market.

Acquisition and collaboration of related companies, along with the launch of new products after extensive research and development activities, has been a key strategy adopted by key players to strengthen their geographic presence in the last few years. Therefore, the players strive to gain competitive advantage in the market by opting for strategies such as agreements, partnerships and collaborations, and new product development.

The global hemostatic agents market has been broadly segmented based on product type, specialty / therapeutic area, size of hospitals, and region. In terms of product type, the global hemostatic market has been divided into active agents, passive agents, and combination. The active agents segment, followed by the combination segment, is expected to expand during the forecast period. In terms of specialty / therapeutic area, the global hemostatic agents market has been classified into cardiology, cath lab, trauma, general surgery, obgyn, transplant, oncology, neurology, orthopedic, plastic surgery, dental, and others (urological surgeries, pulmonary surgeries). General surgery, cardiology, and trauma, segments are expected to dominate the market during the forecast period due to the increase in number of patient population cases in these therapeutic areas. In terms of size of hospitals, the global hemostatic agents market has been divided into large hospitals (500+ bed size), medium hospital (250-499 beds), and small hospitals (less than 250 beds). Large hospitals and medium hospitals segments are expected to hold a major share of the market during the forecast period.

In terms of region, the global hemostatic agents market has been segmented into North America, Europe, Asia Pacific, South Africa and Rest of World (RoW). North America and Europe holds a prominent share of the global hemostatic agents market. The market in North America is primarily driven by the increase in geriatric population, rise in number of surgical procedures, and increase in patient population. The market in Asia Pacific is expected to expand at a significant growth rate during the forecast period. The report also states key players in the market based on various attributes such as company overview, key business strategies, financial overview, recent developments, and product portfolio. Key players functioning in the global hemostatic agents market include Baxter, Ethicon US, LLC., C. R. Bard, Inc., B. Braun Melsungen AG, Pfizer Inc., Z-Medica, LLC., CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

The global hemostatic agents market has been segmented as mentioned below:

Global Hemostatic Agents Market, by Product Type

  • Active Agents
  • Passive Agents
  • Combination

Global Hemostatic Agents Market, by Specialty / Therapeutic Area

  • Cardiology
  • Cath Lab
  • Trauma
  • General Surgery
  • ObGyn
  • Transplant
  • Oncology
  • Neurology
  • Orthopedic
  • Plastic Surgery
  • Dental
  • Others (Urological Surgeries, Pulmonary Surgeries)

Global Hemostatic Agents Market, by Size of Hospitals

  • Large Hospitals (500+ bed size)
  • Medium Hospital (250-499 beds)
  • Small Hospitals (less than 250 beds)

Global Hemostatic Agents Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Australia
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • South Africa
  • Rest of World (RoW)

Table of Contents

1. Research Intent and Scope of the Study

2. Assumptions and Research Methodology

3. Market Overview

4. Premium Insights

  • 4.1. Overall Pricing Assessment
    • 4.1.1. Trends in Pricing of Hemostatic Agents (Overall Level), 2015?2022
  • 4.2. Country Level Pricing Assessment (Key Countries)
    • 4.2.1. U.S.
    • 4.2.2. Canada
    • 4.2.3. Germany
    • 4.2.4. France
    • 4.2.5. U.K.
    • 4.2.6. Spain
    • 4.2.7. Italy
    • 4.2.8. China
    • 4.2.9. India
    • 4.2.10. Australia
    • 4.2.11. Japan
    • 4.2.12. South Korea
    • 4.2.13. South Africa
  • 4.3. Regulatory & Reimbursement Assessment (Key Countries)
    • 4.3.1. U.S.
    • 4.3.2. Canada
    • 4.3.3. Germany
    • 4.3.4. France
    • 4.3.5. U.K.
    • 4.3.6. Spain
    • 4.3.7. Italy
    • 4.3.8. China
    • 4.3.9. India
    • 4.3.10. Australia
    • 4.3.11. Japan
    • 4.3.12. South Korea
    • 4.3.13. South Africa
  • 4.4. Comparative Assessment of Key Products
  • 4.5. Key Distributors (Key Countries)
    • 4.5.1. U.S.
    • 4.5.2. Canada
    • 4.5.3. Germany
    • 4.5.4. France
    • 4.5.5. U.K.
    • 4.5.6. Spain
    • 4.5.7. Italy
    • 4.5.8. China
    • 4.5.9. India
    • 4.5.10. Australia
    • 4.5.11. Japan
    • 4.5.12. South Korea
    • 4.5.13. South Africa

5. North America Hemostatic Agents Market

  • 5.1. U.S. Hemostatic Agents Market
    • 5.1.1. U.S. Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 5.1.1.1. Active Agents
      • 5.1.1.2 Passive Agents
      • 5.1.1.3 Combination
    • 5.1.2. U.S. Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 5.1.2.1. Cardiology
      • 5.1.2.2. Cath Lab
      • 5.1.2.3. Trauma
      • 5.1.2.4. General Surgery
      • 5.1.2.5. ObGyn
      • 5.1.2.6. Transplant
      • 5.1.2.7. Oncology
      • 5.1.2.8. Neurology
      • 5.1.2.9. Orthopedic
      • 5.1.2.10. Plastic Surgery
      • 5.1.2.11. Dental
      • 5.1.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 5.1.3. U.S. Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 5.1.3.1. Large Hospitals (500+ bed size)
      • 5.1.3.2. Medium Hospital (250-399 beds)
      • 5.1.3.3. Small Hospitals (less than 250 beds)
    • 5.1.4. Competition Landscape Assessment - U.S. Hemostatic Agents Market
    • 5.1.5. Brand Assessment: Most Popular Hemostatic Brands-U.S.
    • 5.1.6. Winning Imperatives - Decision Making Criteria-U.S.
    • 5.1.7. Strategic Developments (Hemostatic Agents) - U.S.
    • 5.1.8. Criss-cross Assessment - Product Vs Specialty -U.S.
    • 5.1.9. Market Drivers, Restraints, Opportunities, and Trends - U.S
    • 5.1.10. Decision-making Process - U.S.
      • 5.1.10.1. Purchase Decision-making Process- U.S.
      • 5.1.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- U.S.
      • 5.1.10.3. Selection Criteria for Distributors- U.S.
    • 5.1.11. Sales Channel Assessment - U.S. Hemostatic Agents Market
    • 5.1.12. Customer Landscape
      • 5.1.12.1. Concentration of Hospitals in U.S. - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 5.1.12.2. Key Users of Products, by Specialty/Therapeutic Area - U.S.
  • 5.2. Canada Hemostatic Agents Market
    • 5.2.1. Canada Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 5.2.1.1. Active Agents
      • 5.2.1.2 Passive Agents
      • 5.2.1.3 Combination
    • 5.2.2. Canada Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 5.2.2.1. Cardiology
      • 5.2.2.2. Cath Lab
      • 5.2.2.3. Trauma
      • 5.2.2.4. General Surgery
      • 5.2.2.5. ObGyn
      • 5.2.2.6. Transplant
      • 5.2.2.7. Oncology
      • 5.2.2.8. Neurology
      • 5.2.2.9. Orthopedic
      • 5.2.2.10. Plastic Surgery
      • 5.2.2.11. Dental
      • 5.2.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 5.2.3. Canada Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 5.2.3.1. Large Hospitals (500+ bed size)
      • 5.2.3.2. Medium Hospital (250-499 beds)
      • 5.2.3.3. Small Hospitals (less than 250 beds)
    • 5.2.4. Competition Landscape Assessment - Canada Hemostatic Agents Market
    • 5.2.5. Brand Assessment: Most Popular Hemostatic Brands-Canada
    • 5.2.6. Winning Imperatives - Decision Making Criteria-Canada
    • 5.2.7. Strategic Developments (Hemostatic Agents) - Canada
    • 5.2.8. Criss-cross Assessment - Product vs. Specialty -Canada
    • 5.2.9. Market Drivers, Restraints, Opportunities, and Trends - Canada
    • 5.2.10. Decision-making Process - Canada
      • 5.2.10.1. Purchase Decision-making Process - Canada
      • 5.2.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- Canada
      • 5.2.10.3. Selection Criteria for Distributors - Canada
    • 5.2.11. Sales Channel Assessment - Canada Hemostatic Agents Market
    • 5.2.12. Customer Landscape
      • 5.2.12.1. Concentration of Hospitals in Canada - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 5.2.12.2. Key Users of Products, by Specialty/Therapeutic Area - Canada

6. Europe Hemostatic Agents Market

  • 6.1. Germany Hemostatic Agents Market
    • 6.1.1. Germany Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 6.1.1.1. Active Agents
      • 6.1.1.2 Passive Agents
      • 6.1.1.3 Combination
    • 6.1.2. Germany Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 6.1.2.1. Cardiology
      • 6.1.2.2. Cath Lab
      • 6.1.2.3. Trauma
      • 6.1.2.4. General Surgery
      • 6.1.2.5. ObGyn
      • 6.1.2.6. Transplant
      • 6.1.2.7. Oncology
      • 6.1.2.8. Neurology
      • 6.1.2.9. Orthopedic
      • 6.1.2.10. Plastic Surgery
      • 6.1.2.11. Dental
      • 6.1.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 6.1.3. Germany Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 6.1.3.1. Large Hospitals (500+ bed size)
      • 6.1.3.2. Medium Hospital (250-499 beds)
      • 6.1.3.3. Small Hospitals (less than 250 beds)
    • 6.1.4. Competition Landscape Assessment - Germany Hemostatic Agents Market
    • 6.1.5. Brand Assessment: Most Popular Hemostatic Brands-Germany
    • 6.1.6. Winning Imperatives - Decision Making Criteria - Germany
    • 6.1.7. Strategic Developments (Hemostatic Agents) - Germany
    • 6.1.8. Criss-cross Assessment - Product vs. Specialty - Germany
    • 6.1.9. Market Drivers, Restraints, Opportunities, and Trends - Germany
    • 6.1.10. Decision-making Process - Germany
      • 6.1.10.1. Purchase Decision-making Process - Germany
      • 6.1.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- Germany
      • 6.1.10.3. Selection Criteria for Distributors- Germany
    • 6.1.11. Sales Channel Assessment - Germany Hemostatic Agents Market
    • 6.1.12. Customer Landscape
      • 6.1.12.1. Concentration of Hospitals in Germany - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 6.1.12.2. Key Users of Products, by Specialty/Therapeutic Area - Germany
  • 6.2. France Hemostatic Agents Market
    • 6.2.1. France Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 6.2.1.1. Active Agents
      • 6.2.1.2 Passive Agents
      • 6.2.1.3 Combination
    • 6.2.2. France Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 6.2.2.1. Cardiology
      • 6.2.2.2. Cath Lab
      • 6.2.2.3. Trauma
      • 6.2.2.4. General Surgery
      • 6.2.2.5. ObGyn
      • 6.2.2.6. Transplant
      • 6.2.2.7. Oncology
      • 6.2.2.8. Neurology
      • 6.2.2.9. Orthopedic
      • 6.2.2.10. Plastic Surgery
      • 6.2.2.11. Dental
      • 6.2.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 6.2.3. France Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 6.2.3.1. Large Hospitals (500+ bed size)
      • 6.2.3.2. Medium Hospital (250-499 beds)
      • 6.2.3.3. Small Hospitals (less than 250 beds)
    • 6.2.4. Competition Landscape Assessment - France Hemostatic Agents Market
    • 6.2.5. Brand Assessment: Most Popular Hemostatic Brands - France
    • 6.2.6. Winning Imperatives - Decision Making Criteria-France
    • 6.2.7. Strategic Developments (Hemostatic Agents) - France
    • 6.2.8. Criss-cross Assessment - Product vs. Specialty - France
    • 6.2.9. Market Drivers, Restraints, Opportunities, and Trends - France
    • 6.2.10. Decision-making Process - France
      • 6.2.10.1. Purchase Decision-making Process - France
      • 6.2.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- France
      • 6.2.10.3. Selection Criteria for Distributors - France
    • 6.2.11. Sales Channel Assessment - France Hemostatic Agents Market
    • 6.2.12. Customer Landscape
      • 6.2.12.1. Concentration of Hospitals in France - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 6.2.12.2. Key Users of Products, by Specialty/Therapeutic Area - France
  • 6.3. U.K. Hemostatic Agents Market
    • 6.3.1. U.K. Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 6.3.1.1. Active Agents
      • 6.3.1.2. Passive Agents
      • 6.3.1.3 Combination
    • 6.3.2. U.K. Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 6.3.2.1. Cardiology
      • 6.3.2.2. Cath Lab
      • 6.3.2.3. Trauma
      • 6.3.2.4. General Surgery
      • 6.3.2.5. ObGyn
      • 6.3.2.6. Transplant
      • 6.3.2.7. Oncology
      • 6.3.2.8. Neurology
      • 6.3.2.9. Orthopedic
      • 6.3.2.10. Plastic Surgery
      • 6.3.2.11. Dental
      • 6.3.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 6.3.3. U.K. Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 6.3.3.1. Large Hospitals (500+ bed size)
      • 6.3.3.2. Medium Hospital (250-399 beds)
      • 6.3.3.3. Small Hospitals (less than 250 beds)
    • 6.3.4. Competition Landscape Assessment - U.K. Hemostatic Agents Market
    • 6.3.5. Brand Assessment: Most Popular Hemostatic Brands-U.K.
    • 6.3.6. Winning Imperatives - Decision Making Criteria - U.K.
    • 6.3.7. Strategic Developments (Hemostatic Agents) - U.K.
    • 6.3.8. Criss-cross Assessment - Product vs. Specialty -U.K.
    • 6.3.9. Market Drivers, Restraints, Opportunities, and Trends - U.K.
    • 6.3.10. Decision-making Process- U.K.
      • 6.3.10.1. Purchase Decision-making Process - U.K.
      • 6.3.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - U.K.
      • 6.3.10.3. Selection Criteria for Distributors - U.K.
    • 6.3.11. Sales Channel Assessment - U.K. Hemostatic Agents Market
    • 6.3.12. Customer Landscape
      • 6.3.12.1. Concentration of Hospitals in U.K. - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 6.3.12.2. Key Users of Products, by Specialty/Therapeutic Area - U.K.
  • 6.4. Spain Hemostatic Agents Market
    • 6.4.1. Spain Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 6.4.1.1. Active Agents
      • 6.4.1.2. Passive Agents
      • 6.4.1.3 Combination
    • 6.4.2. Spain Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 6.4.2.1. Cardiology
      • 6.4.2.2. Cath Lab
      • 6.4.2.3. Trauma
      • 6.4.2.4. General Surgery
      • 6.4.2.5. ObGyn
      • 6.4.2.6. Transplant
      • 6.4.2.7. Oncology
      • 6.4.2.8. Neurology
      • 6.4.2.9. Orthopedic
      • 6.4.2.10. Plastic Surgery
      • 6.4.2.11. Dental
      • 6.4.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 6.4.3. Spain Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 6.4.3.1. Large Hospitals (500+ bed size)
      • 6.4.3.2. Medium Hospital (250-499 beds)
      • 6.4.3.3. Small Hospitals (less than 250 beds)
    • 6.4.4. Competition Landscape Assessment - Spain Hemostatic Agents Market
    • 6.4.5. Brand Assessment: Most Popular Hemostatic Brands-Spain
    • 6.4.6. Winning Imperatives - Decision Making Criteria - Spain
    • 6.4.7. Strategic Developments (Hemostatic Agents) - Spain
    • 6.4.8. Criss-cross Assessment - Product vs. Specialty -Spain
    • 6.4.9. Market Drivers, Restraints, Opportunities, and Trends - U.K.
    • 6.4.10. Decision-making Process - Spain
      • 6.4.10.1. Purchase Decision-making Process - Spain
      • 6.4.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Spain
      • 6.4.10.3. Selection Criteria for Distributors - Spain
    • 6.4.11. Sales Channel Assessment - Spain Hemostatic Agents Market
    • 6.4.12. Customer Landscape
      • 6.4.12.1. Concentration of Hospitals in Spain - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 6.4.12.2. Key Users of Products, by Specialty/Therapeutic Area - Spain
  • 6.5. Italy Hemostatic Agents Market
    • 6.5.1. Italy Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 6.5.1.1. Active Agents
      • 6.5.1.2 Passive Agents
      • 6.5.1.3 Combination
    • 6.5.2. Italy Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 6.5.2.1. Cardiology
      • 6.5.2.2. Cath Lab
      • 6.5.2.3. Trauma
      • 6.5.2.4. General Surgery
      • 6.5.2.5. ObGyn
      • 6.5.2.6. Transplant
      • 6.5.2.7. Oncology
      • 6.5.2.8. Neurology
      • 6.5.2.9. Orthopedic
      • 6.5.2.10. Plastic Surgery
      • 6.5.2.11. Dental
      • 6.5.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 6.5.3. Italy Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 6.5.3.1. Large Hospitals (500+ bed size)
      • 6.5.3.2. Medium Hospital (250-499 beds)
      • 6.5.3.3. Small Hospitals (less than 250 beds)
    • 6.5.4. Competition Landscape Assessment - Italy Hemostatic Agents Market
    • 6.5.5. Brand Assessment: Most Popular Hemostatic Brands - Italy
    • 6.5.6. Winning Imperatives - Decision Making Criteria - Italy
    • 6.5.7. Strategic Developments (Hemostatic Agents) - Italy
    • 6.5.8. Criss-cross Assessment - Product vs. Specialty -Italy
    • 6.5.9. Market Drivers, Restraints, Opportunities, and Trends - Italy
    • 6.5.10. Decision-making Process- Italy
      • 6.5.10.1. Purchase Decision-making Process - Italy
      • 6.5.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Italy
      • 6.5.10.3. Selection Criteria for Distributors - Italy
    • 6.5.11. Sales Channel Assessment - Italy Hemostatic Agents Market
    • 6.5.12. Customer Landscape
      • 6.5.12.1. Concentration of Hospitals in Italy - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 6.5.12.2. Key Users of Products, by Specialty/Therapeutic Area - Italy

7. Asia Pacific Hemostatic Agents Market

  • 7.1. China Hemostatic Agents Market
    • 7.1.1. China Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 7.1.1.1. Active Agents
      • 7.1.1.2 Passive Agents
      • 7.1.1.3 Combination
    • 7.1.2. China Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 7.1.2.1. Cardiology
      • 7.1.2.2. Cath Lab
      • 7.1.2.3. Trauma
      • 7.1.2.4. General Surgery
      • 7.1.2.5. ObGyn
      • 7.1.2.7. Transplant
      • 7.1.2.7. Oncology
      • 7.1.2.8. Neurology
      • 7.1.2.9. Orthopedic
      • 7.1.2.10. Plastic Surgery
      • 7.1.2.11. Dental
      • 7.1.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 7.1.3. China Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 7.1.3.1. Large Hospitals (500+ bed size)
      • 7.1.3.2. Medium Hospital (250-499 beds)
      • 7.1.3.3. Small Hospitals (less than 250 beds)
    • 7.1.4. Competition Landscape Assessment - China Hemostatic Agents Market
    • 7.1.5. Brand Assessment: Most Popular Hemostatic Brands-China
    • 7.1.6. Winning Imperatives - Decision Making Criteria - China
    • 7.1.7. Strategic Developments (Hemostatic Agents) - China
    • 7.1.8. Criss-cross Assessment - Product vs. Specialty -China
    • 7.1.9. Market Drivers, Restraints, Opportunities, and Trends - China
    • 7.1.10. Decision-making Process - China
      • 7.1.10.1. Purchase Decision-making Process - China
      • 7.1.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- China
      • 7.1.10.3. Selection Criteria for Distributors - China
    • 7.1.11. Sales Channel Assessment - China Hemostatic Agents Market
    • 7.1.12. Customer Landscape
      • 7.1.12.1. Concentration of Hospitals in China - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 7.1.12.2. Key Users of Products, by Specialty/Therapeutic Area - China
  • 7.2. India Hemostatic Agents Market
    • 7.2.1. India Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 7.2.1.1. Active Agents
      • 7.2.1.2 Passive Agents
      • 7.2.1.3 Combination
    • 7.2.2. India Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 7.2.2.1. Cardiology
      • 7.2.2.2. Cath Lab
      • 7.2.2.3. Trauma
      • 7.2.2.4. General Surgery
      • 7.2.2.5. ObGyn
      • 7.2.2.6. Transplant
      • 7.2.2.7. Oncology
      • 7.2.2.8. Neurology
      • 7.2.2.9. Orthopedic
      • 7.2.2.10. Plastic Surgery
      • 7.2.2.11. Dental
      • 7.2.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 7.2.3. India Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 7.2.3.1. Large Hospitals (500+ bed size)
      • 7.2.3.2. Medium Hospital (250-499 beds)
      • 7.2.3.3. Small Hospitals (less than 250 beds)
    • 7.2.4. Competition Landscape Assessment - India Hemostatic Agents Market
    • 7.2.5. Brand Assessment: Most Popular Hemostatic Brands - India
    • 7.2.6. Winning Imperatives - Decision Making Criteria - India
    • 7.2.7. Strategic Developments (Hemostatic Agents) - India
    • 7.2.8. Criss-cross Assessment - Product vs. Specialty -India
    • 7.2.9. Market Drivers, Restraints, Opportunities, and Trends - India
    • 7.2.10. Decision-making Process - India
      • 7.2.10.1. Purchase Decision-making Process - India
      • 7.2.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - India
      • 7.2.10.3. Selection Criteria for Distributors - India
    • 7.2.11. Sales Channel Assessment - India Hemostatic Agents Market
    • 7.2.12. Customer Landscape
      • 7.2.12.1. Concentration of Hospitals in India - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 7.2.12.2. Key Users of Products, by Specialty/Therapeutic Area - India
  • 7.3. Australia Hemostatic Agents Market
    • 7.3.1. Australia Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 7.3.1.1. Active Agents
      • 7.3.1.2. Passive Agents
      • 7.3.1.3 Combination
    • 7.3.2. Australia Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 7.3.2.1. Cardiology
      • 7.3.2.2. Cath Lab
      • 7.3.2.3. Trauma
      • 7.3.2.4. General Surgery
      • 7.3.2.5. ObGyn
      • 7.3.2.6. Transplant
      • 7.3.2.7. Oncology
      • 7.3.2.8. Neurology
      • 7.3.2.9. Orthopedic
      • 7.3.2.10. Plastic Surgery
      • 7.3.2.11. Dental
      • 7.3.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 7.3.3. Australia Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 7.3.3.1. Large Hospitals (500+ bed size)
      • 7.3.3.2. Medium Hospital (250-399 beds)
      • 7.3.3.3. Small Hospitals (less than 250 beds)
    • 7.3.4. Competition Landscape Assessment - Australia Hemostatic Agents Market
    • 7.3.5. Brand Assessment: Most Popular Hemostatic Brands - Australia
    • 7.3.6. Winning Imperatives - Decision Making Criteria - Australia
    • 7.3.7. Strategic Developments (Hemostatic Agents) - Australia
    • 7.3.8. Criss-cross Assessment - Product vs. Specialty - Australia
    • 7.3.9. Market Drivers, Restraints, Opportunities, and Trends - Australia
    • 7.3.10. Decision-making Process - Australia
      • 7.3.10.1. Purchase Decision-making Process - Australia
      • 7.3.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Australia
      • 7.3.10.3. Selection Criteria for Distributors - Australia
    • 7.3.11. Sales Channel Assessment - Australia Hemostatic Agents Market
    • 7.3.12. Customer Landscape
      • 7.3.12.1. Concentration of Hospitals in Australia - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 7.3.12.2. Key Users of Products, by Specialty/Therapeutic Area - Australia
  • 7.4. Japan Hemostatic Agents Market
    • 7.4.1. Japan Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 7.4.1.1. Active Agents
      • 7.4.1.2. Passive Agents
      • 7.4.1.3 Combination
    • 7.4.2. Japan Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 7.4.2.1. Cardiology
      • 7.4.2.2. Cath Lab
      • 7.4.2.3. Trauma
      • 7.4.2.4. General Surgery
      • 7.4.2.5. ObGyn
      • 7.4.2.6. Transplant
      • 7.4.2.7. Oncology
      • 7.4.2.8. Neurology
      • 7.4.2.9. Orthopedic
      • 7.4.2.10. Plastic Surgery
      • 7.4.2.11. Dental
      • 7.4.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 7.4.3. Japan Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 7.4.3.1. Large Hospitals (500+ bed size)
      • 7.4.3.2. Medium Hospital (250-499 beds)
      • 7.4.3.3. Small Hospitals (less than 250 beds)
    • 7.4.4. Competition Landscape Assessment - Japan Hemostatic Agents Market
    • 7.4.5. Brand Assessment: Most Popular Hemostatic Brands - Japan
    • 7.4.6. Winning Imperatives - Decision Making Criteria - Japan
    • 7.4.7. Strategic Developments (Hemostatic Agents) - Japan
    • 7.4.8. Criss-cross Assessment - Product vs. Specialty - Japan
    • 7.4.9. Market Drivers, Restraints, Opportunities, and Trends - Australia
    • 7.4.10. Decision-making Process - Japan
      • 7.4.10.1. Purchase Decision-making Process - Japan
      • 7.4.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Japan
      • 7.4.10.3. Selection Criteria for Distributors - Japan
    • 7.4.11. Sales Channel Assessment - Japan Hemostatic Agents Market
    • 7.4.12. Customer Landscape
      • 7.4.12.1. Concentration of Hospitals in Japan - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 7.4.12.2. Key Users of Products, by Specialty/Therapeutic Area - Japan
  • 7.5. South Korea Hemostatic Agents Market
    • 7.5.1. South Korea Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
      • 7.5.1.1. Active Agents
      • 7.5.1.2 Passive Agents
      • 7.5.1.3 Combination
    • 7.5.2. South Korea Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
      • 7.5.2.1. Cardiology
      • 7.5.2.2. Cath Lab
      • 7.5.2.3. Trauma
      • 7.5.2.4. General Surgery
      • 7.5.2.5. ObGyn
      • 7.5.2.7. Transplant
      • 7.5.2.7. Oncology
      • 7.5.2.8. Neurology
      • 7.5.2.9. Orthopedic
      • 7.5.2.10. Plastic Surgery
      • 7.5.2.11. Dental
      • 7.5.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
    • 7.5.3. South Korea Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
      • 7.5.3.1. Large Hospitals (500+ bed size)
      • 7.5.3.2. Medium Hospital (250-499 beds)
      • 7.5.3.3. Small Hospitals (less than 250 beds)
    • 7.5.4. Competition Landscape Assessment - South Korea Hemostatic Agents Market
    • 7.5.5. Brand Assessment: Most Popular Hemostatic Brands - Italy
    • 7.5.6. Winning Imperatives - Decision Making Criteria - Italy
    • 7.5.7. Strategic Developments (Hemostatic Agents) - South Korea
    • 7.5.8. Criss-cross Assessment - Product vs. Specialty - South Korea
    • 7.5.9. Market Drivers, Restraints, Opportunities, and Trends - South Korea
    • 7.5.10. Decision-making Process - South Korea
      • 7.5.10.1. Purchase Decision-making Process - South Korea
      • 7.5.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - South Korea
      • 7.5.10.3. Selection Criteria for Distributors- South Korea
    • 7.5.11. Sales Channel Assessment - South Korea Hemostatic Agents Market
    • 7.5.12. Customer Landscape
      • 7.5.12.1. Concentration of Hospitals in South Korea - Heat Map & Detailed Hospital Segmentation, by Bed Size
      • 7.5.12.2. Key Users of Products, by Specialty/Therapeutic Area - South Korea

8. South Africa Hemostatic Agents Market

  • 8.1. South Africa Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
    • 8.1.1. Active Agents
    • 8.1.2. Passive Agents
    • 8.1.3. Combination
  • 8.2. South Africa Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
    • 8.2.1. Cardiology
    • 8.2.2. Cath Lab
    • 8.2.3. Trauma
    • 8.2.4. General Surgery
    • 8.2.5. ObGyn
    • 8.2.6. Transplant
    • 8.2.8. Oncology
    • 8.2.8. Neurology
    • 8.2.9. Orthopedic
    • 8.2.10. Plastic Surgery
    • 8.2.11. Dental
    • 8.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
  • 8.3. South Africa Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
    • 8.3.1. Large Hospitals (500+ bed size)
    • 8.3.2. Medium Hospital (250-499 beds)
    • 8.3.3. Small Hospitals (less than 250 beds)
  • 8.4. Competition Landscape Assessment - South Africa Hemostatic Agents Market
  • 8.5. Brand Assessment: Most Popular Hemostatic Brands - South Africa
  • 8.6. Winning Imperatives - Decision Making Criteria - South Africa
  • 8.7. Strategic Developments (Hemostatic Agents) - South Africa
  • 8.8. Criss-cross Assessment - Product vs. Specialty - South Africa
  • 8.9. Market Drivers, Restraints, Opportunities, and Trends - South Africa
  • 8.10. Decision-making Process - South Africa
    • 8.10.1. Purchase Decision-making Process - South Africa
    • 8.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - South Africa
    • 8.10.3. Selection Criteria for Distributors - South Africa
  • 8.11. Sales Channel Assessment - South Africa Hemostatic Agents Market
  • 8.12. Customer Landscape
    • 8.12.1. Concentration of Hospitals in South Africa - Heat Map & Detailed Hospital Segmentation, by Bed Size
    • 8.12.2. Key Users of Products, by Specialty/Therapeutic Area - South Africa

9. Rest of the World (RoW) Hemostatic Agents Market

  • 9.1. Rest of the World (RoW) Hemostatic Agents Market Value Forecast, by Product Type, 2015-2022
    • 9.1.1. Active Agents
    • 9.1.2 Passive Agents
    • 9.1.3 Combination
  • 9.2. Rest of the World (RoW) Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015-2022
    • 9.2.1. Cardiology
    • 9.2.2. Cath Lab
    • 9.2.3. Trauma
    • 9.2.4. General Surgery
    • 9.2.5. ObGyn
    • 9.2.6. Transplant
    • 9.2.7. Oncology
    • 9.2.8. Neurology
    • 9.2.9. Orthopedic
    • 9.2.10. Plastic Surgery
    • 9.2.11. Dental
    • 9.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
  • 9.3. Rest of the World (RoW) Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015-2022
    • 9.3.1. Large Hospitals (500+ bed size)
    • 9.3.2. Medium Hospital (250-499 beds)
    • 9.3.3. Small Hospitals (less than 250 beds)

10. Company Profiles

  • 10.1. Baxter
  • 10.2. Ethicon US, LLC.
  • 10.3. C. R. Bard, Inc.
  • 10.4. B. Braun Melsungen AG
  • 10.5. Pfizer Inc.
  • 10.6. Z-Medica, LLC.
  • 10.7. CryoLife, Inc.
  • 10.8. Integra LifeSciences
  • 10.9. Advanced Medical Solutions Group plc
  • 10.10. GELITA AG
Back to Top